The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
Ultra-Low Costs: All-in production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
Elite Genetics: Proven high-THC cultivars (mid-20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
Ideal Climate: Located in a premium microclimate with stable, predictable conditions enabling year-round cultivation.
Institutional-Grade Infrastructure & Scalability
Immediate Capacity: 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
Expansion Ready: Fully licensed 15-hectare site with capacity for 25+ tonnes, enabling significant scale-up with minimal additional capex.
Operational Autonomy: Dedicated on-site power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.
Advanced Post-Harvest & Processing Technology
Dual-Track Facility: Separate buildings for GACP post-harvest and EU-GMP / TGA GMP-compliant processing.
Unique Technology Edge: Includes Colombia’s only PLC 2500 purification system and an X-ray sterilization unit required for the Australian market.
On-Site Laboratory: Fully equipped lab enabling real-time potency and purity testing to ensure pharmaceutical-grade standards.
Validated Global Export Track Record
Proven Market Access: One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
De-Risked Revenue: Sale includes a binding 3-year offtake agreement and established distribution relationships in Germany and the UK.
Turnkey Transition & Strategic Value
Investment Value: Over USD $12M already invested in infrastructure, licensing, and elite genetics.
Financial Status: Debt-free; all related-party debt is forgiven at closing.
Shortcut to Market: Bypasses the typical 3-year development cycle including site selection, construction, and regulatory approvals in Colombia.
Management Continuity: Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
Tax Efficiency: Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.
Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
Ultra-Low Costs: All-in production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
Elite Genetics: Proven high-THC cultivars (mid-20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
Ideal Climate: Located in a premium microclimate with stable, predictable conditions enabling year-round cultivation.
Institutional-Grade Infrastructure & Scalability
Immediate Capacity: 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
Expansion Ready: Fully licensed 15-hectare site with capacity for 25+ tonnes, enabling significant scale-up with minimal additional capex.
Operational Autonomy: Dedicated on-site power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.
Advanced Post-Harvest & Processing Technology
Dual-Track Facility: Separate buildings for GACP post-harvest and EU-GMP / TGA GMP-compliant processing.
Unique Technology Edge: Includes Colombia’s only PLC 2500 purification system and an X-ray sterilization unit required for the Australian market.
On-Site Laboratory: Fully equipped lab enabling real-time potency and purity testing to ensure pharmaceutical-grade standards.
Validated Global Export Track Record
Proven Market Access: One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
De-Risked Revenue: Sale includes a binding 3-year offtake agreement and established distribution relationships in Germany and the UK.
Turnkey Transition & Strategic Value
Investment Value: Over USD $12M already invested in infrastructure, licensing, and elite genetics.
Financial Status: Debt-free; all related-party debt is forgiven at closing.
Shortcut to Market: Bypasses the typical 3-year development cycle including site selection, construction, and regulatory approvals in Colombia.
Management Continuity: Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
Tax Efficiency: Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.
Description
Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
Institutional-Grade Infrastructure & Scalability
Advanced Post-Harvest & Processing Technology
Validated Global Export Track Record
Turnkey Transition & Strategic Value
Financial Forecast
Basic Details
Target Price:
$ 7,000,000
Gross Revenue
$12,500,000
EBITDA
$6,000,000
Business ID:
L#20261067
Country
Colombia
Detail
Published on May 21, 2026 at 11:23 am. Updated on August 8, 2026 at 6:49 pm